Verve Therapeutics Inc. (NASDAQ:VERV)
Old Forum Content for VERV
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- shoredriver: $VERV....rolling bio dumpster fire du jour...np
- Kid2old: @scottrades $ARKK $CRSP – NEWS 4/6/23 Cathie Wood loads up on Biotech stocks. Funds operated by ARK bought shares of Crispr Therapeutics AG ($CRSP), Intellia Therapeutics Inc ($NTLA), Verve Therapeutics Inc ($VERV), Beam Therapeutics Inc ($BEAM) and Ginkgo Bioworks Holdings Inc ($DNA). The purchase was conducted via the flagship ARK Innovation ETF ($ARKK) and the ARK Genomic Revolution ETF ($ARKG).
-
DAN: ...
As for today: Check out $ARKK. This ETF holds all of the very speculative and beaten down tech names. Stocks such as $NVTA $TWOU $U $TXG $VCYT $PACB $TWST $VERV and so many others were up between 18-37%. The worst performer in the $ARKK holdings ... - Hawaiianmaxx: @DAN $ARKK $NVTA $TWOU $U $TXG $VCYT $PACB $TWST $VERV $SHOP $NVDA $CERS $TSLA good read, Sir 👍
- DAN: @Hawaiianmaxx $ARKK $NVTA $TWOU $U $TXG $VCYT $PACB $TWST $VERV $SHOP $NVDA $CERS $TSLA Thank you! ;-)
-
Docoof: Fwiw, $ARKK and $ARKQ are starting to build new positions in $VERV, which is near its ytd high and above its 50d sma. $VERV closed +0.17% today. $VERV IPO’d on June 17, 2021.
$VERV is up 62.24% over the past 6 months.
Verve Therapeutics &mdas ... - bla00109: @wineinquirer $VERV $XBI $LABU There was a fascinating interview with Ethan Brown, the vegan CEO of Beyond Meat which I'd recommend. https://www.nytimes.com/2021/08/27/business/ethan-brown-beyond-meat-corner-office.html?searchResultPosition=1 He mentions how vegan diet changes the biome and reduces trimethylamine oxide (TMAO). TMAO levels seem to correlate quite strongly with cardiovascular risk. I read some papers about TMAO over the weekend but it's not really clear if TMAO levels are actually causal or just correlative with CV disease. It's worth a read.
-
wineinquirer: $VERV
ipo that genetically targets cholesterol producing genes in the liver, lowering the risks of CVD (cardiovascular disease). From the company website " Our most advanced gene editing programs targeting two independent pathways controlling b ... - bRobert: @wineinquirer $VERV I like the stock from a technical perspective A high base set up. pinching above the 20d. A nh print. above $75. has $100. target potential. 40% upside. np. This is. a. SPEC. still in diapers. It appears polite but could be volatile on a day to day basis. SMALL works best . Nice
- wanda1616: @wineinquirer $VERV or one could just go vegan : )
- wanda1616: @wineinquirer $VERV $XBI $LABU perhaps there is a variety of hard core congenital CVD that cannot be deterred. i do know that diet can upregulate and downregulate the epigene. here is a really interesting film https://www.youtube.com/watch?v=n1LUj3kxB9M
- wineinquirer: @wanda1616 $VERV $XBI $LABU Designer Genes Haven't seen studies whether vegan reduces CVD if congenital. Through my medical career, I've worked with very obese surgeons who smoked and lived to be 90. I've also known those on the other end of the spectrum.........fully healthy (not necessarily vegan), and suffered early onset CVD. "Designer genes" nearly always win out. $VERV will have competitors, no doubt, as the CRISPR system of gene editing will offer endless life altering/saving opportunities. One of the reasons, I also like the prospects of $XBI/$LABU. The genetic editing revolution is as big a deal as was the industrial revolution & computing industry............life changing,,,,,,,,,,,imho!!!
- wineinquirer: $VERV Interesting ipo focusing upon genetic analysis & gene editing in patients with cardiovasc dis. Constructive chart w/bo ~74 and if so, tgt ~100. Next earnings (Mktsmith) 8/31. BTW Walter Issacson's current book The Code Breaker is a phenom reading for anyone intrigued by the CRISPR system of genetic editing. Reads like a suspense novel and while complex (genetics at times), often simplified for the lay person.
| Stock Price | $6.26 |
| Change | 1.62% |
| Volume | 923,144 |
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
Request Video of VERVAlready a member? Sign in here.
Past Month
Leading Peers
-
$12.76 309.10%
-
$6.18 273.76%
-
$12.32 258.96%
Past Month
Lagging Peers
-
$28.29 -78.88%
-
$6.26 -75.21%
-
$13.82 -57.99%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!